HIV vaccine - HIVACAT/Esteve

Drug Profile

HIV vaccine - HIVACAT/Esteve

Alternative Names: HIVACAT AIDS vaccine programme - Hospital Clinic de Barcelona/IrsiCaixa Foundation/Esteve

Latest Information Update: 19 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator HIVACAT; irsiCaixa Foundation
  • Developer ESTEVE; HIVACAT; irsiCaixa Foundation
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 19 Jan 2016 Phase-I clinical trials in HIV infections (Prevention) in Spain (unspecified route)
  • 19 Jan 2016 Phase-I clinical trials in HIV infections in Spain (unspecified route)
  • 30 Apr 2010 Preclinical trials in HIV infections (prevention) in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top